FDC Ltd Stock Price Today (NSE: FDC)

FDC Ltd

409.80+2.35 (+0.58%)
Market Closed

Fundamental Score

...

FDC Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

FDC Ltd share price today is 409.80, up +0.58% on NSE/BSE as of 31 July 2026. FDC Ltd (FDC) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 6.91K (Cr). The 52-week high for FDC share price is 527.80 and the 52-week low is 312.95. At a P/E ratio of 23.25x, FDC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.46% and a debt-to-equity ratio of 0.01.

FDC Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
442.00
Low
397.05
Volume
1.3L
Change
-4.82%

FDC Ltd share price chart: -4.82% return over the past month. 52-week high ₹527.80, 52-week low ₹312.95.

FDC Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
408.00413.20406.00409.801.38L (Cr)
412.00415.00405.35407.451.03L (Cr)
409.00416.00408.50414.3055.10K (Cr)
417.10417.95404.90407.4586.92K (Cr)
417.00419.80411.60417.1060.67K (Cr)
399.50416.05397.05412.9596.73K (Cr)
410.30411.90399.90401.251.23L (Cr)
414.40419.10410.35413.2592.43K (Cr)
421.40426.00415.50417.9074.13K (Cr)
422.00422.60413.55420.1086.85K (Cr)

FDC Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
423.00442.00397.05409.80-3.12%
408.00432.00373.25423.85+3.88%
364.50439.45353.80405.00+11.11%
325.50376.30320.50364.45+11.97%
350.65385.00312.95321.10-8.43%
376.90399.50350.35356.65-5.37%
422.00422.70358.75377.75-10.49%
414.45433.45403.55423.10+2.09%
463.85473.60405.00414.40-10.66%
446.20476.40429.15460.65+3.24%
461.10527.80441.10442.30-4.08%
475.95496.80455.20457.75-3.82%

Returns & Performance

Poor

Return on Equity (ROE)

12.46%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.67%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.89%

Average operating profit margin over 5 years

Good

Dividend Yield

1.18%

Annual dividend as % of current share price

FDC Ltd Valuation Check

Excellent

Price to Earnings (P/E)

23.25x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

69.66%

% shares held by company founders/management

Poor

FII Holding

2.40%

% shares held by foreign institutional investors

Average

DII Holding

6.29%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

167.39%

Net profit growth vs same quarter last year

Good

Revenue Growth (Quarterly YoY)

18.89%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.28%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

1.67%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

0.93%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

80.24x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

499.62 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

FDC Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of FDC across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Excellent ROCE Performance (16.67%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (15.89%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 23.25 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (167.39%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (18.89%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (80.24x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹499.62 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (69.66%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Weak Earnings Growth (1.67% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (0.93% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Limited Institutional Interest (FII+DII: 8.69%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

FDC Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare FDC Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
60.4/100
410
₹6906.42
23.3
Average
12.46%
Average
16.67%
Good
0.0
Excellent
0.93%
Average
10.28%
Good
1.18%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

FDC Ltd PE Ratio History

Historical price-to-earnings ratio for FDC — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202516.39₹423.1025.8x
FY 20241858.00₹499.450.3x
FY 202311.67₹396.4534x
FY 202212.82₹270.8521.1x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

FDC Ltd Dividend History

Annual cash dividends paid by FDC — dividend yield 1.18%

Financial YearDividends Paid (₹ Cr)
FY 202581.13 Cr
FY 20240.15 Cr
FY 20230.18 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

FDC Ltd Quarterly Performance

Latest quarterly metrics for FDC — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

18.89%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

167.39%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.28%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

0.93%

Compounded annual net profit growth over 5 years

FDC Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for FDC — calculated from daily price history

35RSI 14
Neutral — RSI 35

Momentum is balanced — neither overbought nor oversold.

SMA 50
407
▲ Price above SMA 50 — Short-term bullish
SMA 200
394
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
202K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

FDC Ltd Financial Statements

Annual income statement, balance sheet and cash flow for FDC Ltd (FDC) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for FDC Ltd

About FDC (FDC Ltd)

FDC Ltd is a pioneering pharmaceutical company deeply rooted in the Indian subcontinent, with expanding influence across international markets. It's an organisation driven by innov...ation, continually researching and developing novel therapeutic solutions. Their core strength lies in crafting accessible, high-quality medications that address a diverse range of health needs. FDC is synonymous with robust manufacturing practices, ensuring adherence to the most stringent global regulatory standards. They are deeply committed to improving patient outcomes. FDC invests heavily in cutting-edge technology and advanced research facilities to stay at the forefront of pharmaceutical innovation. They have forged a reputation for reliability and efficacy among healthcare professionals and patients alike. The company's product portfolio is remarkably diverse, spanning across essential therapeutic categories. From tackling infectious diseases with potent anti-infectives to providing relief for digestive ailments and enhancing eye health with specialised ophthalmic treatments, FDC offers a comprehensive range of solutions. They are also significant players in addressing chronic conditions, providing effective cardiovascular and anti-diabetic therapies. With a keen eye on evolving health challenges, FDC develops innovative respiratory care products, supports women's health through gynaecological solutions, and offers specialised dermatological treatments. FDC also manufactures vital supplements and trusted analgesics to further support overall well-being and quality of life. FDC's commitment extends beyond manufacturing and distribution. They have cultivated strong relationships with healthcare providers, researchers, and regulatory bodies to foster collaboration and knowledge sharing. FDC dedicates resources to patient education programs, empowering individuals to make informed decisions about their health. Their dedication to ethical practices, environmental sustainability, and social responsibility are cornerstones of their business philosophy. FDC strives to be a trusted partner in global healthcare, dedicated to enhancing lives and providing accessible, effective pharmaceutical solutions to a global patient population.

Company Details

Symbol:FDC
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Nandan Mohan Chandavarkar
Joint MD & Executive Director
Mr. Mohan Anand Chandavarkar
BR Head, MD & Director
Mr. Ameya Ashok Chandavarkar
CEO of International Business & Executive Director

Corporate Events

Recent
Ex-Dividend Date

FDC Share Price: Frequently Asked Questions

What is the current share price of FDC Ltd?

FDC Ltd (FDC) trades at ₹409.80 on NSE and BSE. Market cap ₹6.91K (Cr). Educational data only.

What is the P/E ratio of FDC Ltd?

FDC Ltd has a P/E of 23.25x vs industry average 34.89x.

What is the Bull Run score for FDC Ltd?

FDC Ltd has a Bull Run score of 60.4/100 based on 25+ financial parameters.

Does FDC Ltd pay dividends?

FDC Ltd has a dividend yield of 1.18%. Past dividends don't guarantee future payments.

What is the ROE of FDC Ltd?

FDC Ltd has ROE of 12.46%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of FDC Ltd?

FDC Ltd has debt-to-equity of 0.01.

Is FDC Ltd a good investment?

Bull Run gives FDC Ltd a score of 60.4/100. This is not investment advice — consult a SEBI-registered advisor.